Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MVA-based SARS-CoV-2 Vaccine
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : GeoVax Labs
Deal Size : Undisclosed
Deal Type : Agreement
GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates
Details : The partnership will support current Good Manufacturing Practices production of the company’s vaccine candidates, including GEO-MVA and GEO-CM04S1 (MVA-based SARS-CoV-2 vaccine), a next-generation COVID-19 vaccine based on GeoVax’s MVA viral vector p...
Brand Name : GEO-CM04S1
Molecule Type : Vaccine
Upfront Cash : Undisclosed
May 31, 2023
Lead Product(s) : MVA-based SARS-CoV-2 Vaccine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : GeoVax Labs
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : HIV-1 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : DAIDS
Deal Size : $364.5 million
Deal Type : Partnership
ABL Awarded NIH Contract for Continued Support of HIV Vaccine Development
Details : ABL will provide DAIDS with preclinical and translational development of promising vaccines and related products for HIV and other candidate agents.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
October 20, 2022
Lead Product(s) : HIV-1 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : DAIDS
Deal Size : $364.5 million
Deal Type : Partnership
LOOKING FOR A SUPPLIER?
Reset All
